JP2020520988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520988A5 JP2020520988A5 JP2020504095A JP2020504095A JP2020520988A5 JP 2020520988 A5 JP2020520988 A5 JP 2020520988A5 JP 2020504095 A JP2020504095 A JP 2020504095A JP 2020504095 A JP2020504095 A JP 2020504095A JP 2020520988 A5 JP2020520988 A5 JP 2020520988A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- optionally
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023101616A JP7781821B2 (ja) | 2017-04-05 | 2023-06-21 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
| JP2025203641A JP2026041812A (ja) | 2017-04-05 | 2025-11-26 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482018P | 2017-04-05 | 2017-04-05 | |
| US62/482,018 | 2017-04-05 | ||
| PCT/US2018/026014 WO2018187423A1 (en) | 2017-04-05 | 2018-04-04 | Methods and reagents for analyzing protein-protein interfaces |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023101616A Division JP7781821B2 (ja) | 2017-04-05 | 2023-06-21 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520988A JP2020520988A (ja) | 2020-07-16 |
| JP2020520988A5 true JP2020520988A5 (enExample) | 2021-05-13 |
Family
ID=63712343
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504095A Pending JP2020520988A (ja) | 2017-04-05 | 2018-04-04 | タンパク質−タンパク質界面を分析するための方法及び試薬 |
| JP2023101616A Active JP7781821B2 (ja) | 2017-04-05 | 2023-06-21 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
| JP2025203641A Pending JP2026041812A (ja) | 2017-04-05 | 2025-11-26 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023101616A Active JP7781821B2 (ja) | 2017-04-05 | 2023-06-21 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
| JP2025203641A Pending JP2026041812A (ja) | 2017-04-05 | 2025-11-26 | タンパク質－タンパク質界面を分析するための方法及び試薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210285955A1 (enExample) |
| EP (1) | EP3607326A4 (enExample) |
| JP (3) | JP2020520988A (enExample) |
| KR (2) | KR20240093922A (enExample) |
| CN (1) | CN110785428A (enExample) |
| AU (2) | AU2018250186B2 (enExample) |
| BR (1) | BR112019020967A2 (enExample) |
| CA (1) | CA3058964A1 (enExample) |
| IL (2) | IL269779B2 (enExample) |
| MX (1) | MX2025014195A (enExample) |
| WO (1) | WO2018187423A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| IL317393A (en) * | 2018-12-21 | 2025-02-01 | Revolution Medicines Inc | Compounds that participate in covalent bonds and their uses |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN121471132A (zh) | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN119661684B (zh) * | 2024-10-21 | 2025-11-25 | 山东大学 | 一种高抗炎活性的脂联素突变体及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999010374A1 (en) * | 1997-08-26 | 1999-03-04 | Wisconsin Alumni Research Foundation | Cyclosporin a conjugates and uses therefor |
| US7220552B1 (en) * | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| US7176037B2 (en) * | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
| CA2633500A1 (en) * | 2005-12-20 | 2007-07-05 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
| JP4871960B2 (ja) * | 2006-01-03 | 2012-02-08 | エフ．ホフマン−ラ ロシュ アーゲー | 優れたシャペロン活性およびフォールディング活性を有するキメラ融合タンパク質 |
| US20090054334A1 (en) * | 2007-05-23 | 2009-02-26 | Mutz Mitchell W | Combinatorial improvement of bifunctional drug properties |
| US9428845B1 (en) * | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| US9260484B2 (en) * | 2011-06-15 | 2016-02-16 | Ohio State Innovation Foundation | Small molecule composite surfaces as inhibitors of protein-protein interactions |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| US10427131B2 (en) * | 2015-03-19 | 2019-10-01 | 3M Innovative Properties Company | Guanidine-functionalized perlite particles, articles containing the particles, and methods of using the particles and articles |
| CA3000822A1 (en) * | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CN105902537A (zh) * | 2016-04-26 | 2016-08-31 | 兰州大学 | 靶向人fkbp51蛋白的先导化合物及其筛选方法与应用 |
| US20200199102A1 (en) * | 2017-04-05 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
-
2018
- 2018-04-04 WO PCT/US2018/026014 patent/WO2018187423A1/en not_active Ceased
- 2018-04-04 CA CA3058964A patent/CA3058964A1/en active Pending
- 2018-04-04 BR BR112019020967-0A patent/BR112019020967A2/pt unknown
- 2018-04-04 KR KR1020247017424A patent/KR20240093922A/ko not_active Ceased
- 2018-04-04 IL IL269779A patent/IL269779B2/en unknown
- 2018-04-04 AU AU2018250186A patent/AU2018250186B2/en active Active
- 2018-04-04 KR KR1020197032295A patent/KR20200003802A/ko not_active Ceased
- 2018-04-04 JP JP2020504095A patent/JP2020520988A/ja active Pending
- 2018-04-04 US US16/500,634 patent/US20210285955A1/en not_active Abandoned
- 2018-04-04 CN CN201880037176.0A patent/CN110785428A/zh active Pending
- 2018-04-04 IL IL324618A patent/IL324618A/en unknown
- 2018-04-04 EP EP18781381.1A patent/EP3607326A4/en active Pending
-
2019
- 2019-10-04 MX MX2025014195A patent/MX2025014195A/es unknown
-
2023
- 2023-06-21 JP JP2023101616A patent/JP7781821B2/ja active Active
-
2024
- 2024-02-22 US US18/584,357 patent/US20240426833A1/en active Pending
- 2024-11-19 AU AU2024266705A patent/AU2024266705A1/en active Pending
-
2025
- 2025-11-26 JP JP2025203641A patent/JP2026041812A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501863A5 (enExample) | ||
| US20220403052A1 (en) | Anti-dll4/vegf dual variable domain immmunoglobulin and uses thereof | |
| JP2017505622A5 (enExample) | ||
| HRP20220326T1 (hr) | Domene vezujuće na protein koje stabiliziraju funkcionalna konformacijska stanja gpcr-a i njihove uporabe | |
| JP2021531826A5 (enExample) | ||
| ES2856482T3 (es) | Combinaciones de inhibidores de FGFR y cMet para el tratamiento del cáncer | |
| SG11201408279QA (en) | Social sharing of security information in a group | |
| JP2015508757A5 (enExample) | ||
| JP2017506505A5 (enExample) | ||
| JP2021533166A5 (enExample) | ||
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| WO2014086499A8 (en) | Neurotensin receptor ligands | |
| JP2014504622A5 (enExample) | ||
| UA124529C2 (uk) | Модулятори екто-5-нуклеотидази та їх застосування | |
| HRP20180443T1 (hr) | Povezujuće domene usmjerene protiv gpcr-a: g proteinski kompleksi i njihove derivirane uporabe | |
| HRP20171777T1 (hr) | Novi himerni polipeptidi za potrebe probira i otkrivanja lijekova | |
| EP2650009A3 (en) | Screening methods using G-protein coupled receptors and related compositions | |
| EA201190116A1 (ru) | Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1 | |
| JP2018532788A5 (enExample) | ||
| EA201290172A1 (ru) | Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1 | |
| Zhou et al. | Improved eIF4E binding peptides by phage display guided design: plasticity of interacting surfaces yield collective effects | |
| Scapin et al. | Multifaceted roles of crystallography in modern drug discovery | |
| J. Geldenhuys et al. | The blood-brain barrier choline transporter | |
| CA2944462A1 (en) | Novel hdmx inhibitors and their use for cancer treatment | |
| JP2021505578A5 (enExample) |